Showing results (251-260 of 675) with videos related to
Sort By:
Pageof 68
JCO Precision Oncology|December 12, 2024
Prevalence and Distribution of Unexpected Actionable Germline Pathogenic Variants Identified on Broad-Based Multigene Panel Testing Among Patients With CancerKara K Landry, Michael J DeSarno, Lindsay Kipnis, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.Journal of the National Cancer Institute|December 5, 2002
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersSteven A Narod, Marie-Pierre Dubé, Jan Klijn, et al.Breast Cancer Research and Treatment|November 3, 2016
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer familyCiyu Yang, Angela G Arnold, Magan Trottier, et al.Nature Communications|June 8, 2023
Identification of BRCA1/2 mutation female carriers using circulating microRNA profilesKevin Elias, Urszula Smyczynska, Konrad Stawiski, et al.JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.Journal of the National Cancer Institute|September 22, 2005
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer familiesNoah D Kauff, Nandita Mitra, Mark E Robson, et al.Cancer|September 5, 2014
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panelNadine Tung, Chiara Battelli, Brian Allen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Henry T Lynch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.Pageof 68